Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership

Rhea-AI Filing Summary

CorMedix Inc. reports a Schedule 13G/A showing Deep Track-affiliated holders beneficially own 6,274,076 shares of common stock. The filing states this equals 7.94% of the class based on March 2, 2026 outstanding shares of 79,050,395. The joint filing names Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin and indicates shared voting and dispositive power over the reported shares.

Insights

Institutional Ownership Analyst

Deep Track reports a sizeable passive stake of 7.94% in CorMedix.

The filing shows 6,274,076 shares beneficially owned as of March 31, 2026, representing 7.94% of 79,050,395 outstanding shares as of March 2, 2026. Ownership is reported as shared voting and dispositive power across affiliated entities.

Because this is a Schedule 13G/A joint filing, it presents as an ownership disclosure rather than an acquisition narrative; subsequent amendments may update positions.

Corporate Governance Specialist

Filing cites joint filing and control-person language tied to Deep Track Capital.

The document identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be a control person and includes a joint filing statement pursuant to Rule 13d-1(k). The reported power is shared voting and dispositive power of 6,274,076 shares.

Investors should note the form type signals disclosure of passive or shared ownership; any change in intent or control would require an amended filing.

Key Figures

Reported beneficial ownership: 6,274,076 shares Percent of class: 7.94% Shares outstanding used: 79,050,395 shares

3 metrics

Reported beneficial ownership 6,274,076 shares Beneficially owned as reported in Schedule 13G/A (as of March 31, 2026 cover reference)

Percent of class 7.94% Percent of common stock based on outstanding shares as of March 2, 2026

Shares outstanding used 79,050,395 shares Outstanding shares as of <date>March 2, 2026</date> per issuer 10-K cited in the filing

Key Terms

beneficially owned, shared dispositive power, joint filing statement

3 terms

beneficially owned regulatory

"Amount beneficially owned: 6,274,076"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 6,274,076.00"

joint filing statement regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 08:39 AM Learn about SEC filing dates

FAQ

What stake does Deep Track report in CorMedix (CRMD)?

The filing reports Deep Track-affiliated holders beneficially own 6,274,076 shares, equal to 7.94% of the common stock based on 79,050,395 outstanding shares as of March 2, 2026.

Which entities are named in the CorMedix filing?

The joint Schedule 13G/A lists Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin as reporting persons and signatures show David Kroin signing in multiple capacities on May 15, 2026.

How is voting and dispositive power reported for the shares?

The filing states the reporting persons have shared voting power and shared dispositive power over 6,274,076 shares, with no sole voting or sole dispositive power reported in the cover data.

What outstanding share count does the filing use to calculate percent ownership?

The percent ownership of 7.94% is calculated using 79,050,395 common shares outstanding as of March 2, 2026, cited from the issuer's Form 10-K filed March 5, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CorMedix Inc.

(Name of Issuer)

Common stock, $0.001 par value

(Title of Class of Securities)

21900C308

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 21900C308

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,274,076.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,274,076.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,274,076.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.94 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 21900C308

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,274,076.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,274,076.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,274,076.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.94 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 21900C308

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,274,076.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,274,076.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,274,076.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.94 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CorMedix Inc.
(b)	Address of issuer's principal executive offices: 389 Interspace Pkwy, Suite 450, Parsippany, NJ 07054
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common stock, $0.001 par value
(e)	CUSIP No.: 21900C308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,274,076
(b)	Percent of class: 7.94%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 6,274,076
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,274,076
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	05/15/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	05/15/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	05/15/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of March 31, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 79,050,395 Common Shares outstanding as of March 2, 2026, according to the issuer's 10-K filed with the SEC on March 5, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin